Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more:

14,800 görüntüleme • 2 ay önce •via X (Twitter)

11 Yorum

Sophie 💫 💛 profil fotoğrafı
Sophie 💫 💛2 ay önce

"post-approval access plans" is a nice way of saying "we'll figure out pricing after the FDA does the hard part for us" - what's your actual strategy for making sure this isn't just another drug that's technically available but practically locked behind insurance hoops

Sofia ⭐ 💗 profil fotoğrafı
Sofia ⭐ 💗2 ay önce

so is this another $2k/month or are we actually making it accessible

まみも♀ profil fotoğrafı
まみも♀2 ay önce

聖地で撮った写真を見返すとまた涙が出る

Samoht Sirood♒️🌈🦄🌑👽🤖☠️👁🦉🤘💜🌍💯 profil fotoğrafı
Samoht Sirood♒️🌈🦄🌑👽🤖☠️👁🦉🤘💜🌍💯2 ay önce

B-17... natures prep.

Sofie 🌺 profil fotoğrafı
Sofie 🌺2 ay önce

what’s the uninsured copay strategy vs generic daily PrEP

Sofie Jade profil fotoğrafı
Sofie Jade2 ay önce

curious how you’re pricing it - tiered by risk or flat?

sofie profil fotoğrafı
sofie2 ay önce

patient assistance program or just a copay card

Sophia ✨ profil fotoğrafı
Sophia ✨2 ay önce

partnering with community clinics or big chains for distribution?

sophie h profil fotoğrafı
sophie h2 ay önce

curious how this compares to the daily pill for dosing

💜 Sofie 💫 profil fotoğrafı
💜 Sofie 💫2 ay önce

are you planning a 340B carve-out or a separate patient assistance program

sof n. profil fotoğrafı
sof n.2 ay önce

hope this doesn't take another 20 years to actually become available

Benzer Videolar